SOURCE: BioTech Medics, Inc.

November 28, 2006 13:29 ET

BioTech Medics, Inc. Exploring Manchester, England European Distribution Site

DALLAS, TX -- (MARKET WIRE) -- November 28, 2006 -- BioTech Medics, Inc. (PINKSHEETS: BTMD) announced it is exploring opening a satellite distribution center and UK offices near the Manchester International Airport, England. The purpose for these offices will be to sell and distribute the patented SHBAN Products. The Manchester Airport area provides a convenient distribution point for SHBAN customers throughout England, Europe and the Middle East.

Earlier this year, BioTech received SHBAN test results from Retroscreen Virology, at the University of London, Queen Mary's School of Medicine, London. BioTech had conducted an independent verifiable study to determine the efficacy of virucidal SHBAN Solution against Avian HSN1 Influenza NIBRG-14 Virus (also known as the Avian Bird Flu).

The SHBAN Solution was clinically proven with its anti-viral properties to topically kill the Avian Influenza virus. But more significantly, SHBAN did so at such low concentrates that "there was no cytotoxicity observed on the MDCK cell line after treatment."

SHBAN is superior to most other anti-viral and anti-bacterial disinfectants because SHBAN is 1) longer lasting, it does not evaporate within one minute after application (as compared to a popular alcohol based sanitizer); 2) it is non-toxic when used as directed on humans and animals; 3) it is non-staining, non-bleaching and 4) has no harmful or toxic odors. Most EPA approved disinfectant products in the USA cannot make all of these claims.

BioTech will be selling SHBAN SOLUTION in 3 0z. Travel Anywhere Hand Sanitizer Spray Bottles, 32 Oz. Home and Office Handy Bottles and 5 gal. Commerical Units.

Safe Harbor: Forward-Looking Statements.

This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks, uncertainties and results could differ materially from those expressed in the forward-looking statements. The statements above have not been evaluated by the FDA. The SHBAN product mentioned is not intended to diagnose, treat or cure any disease.

Contact Information

  • Contact:
    Investor Relations